Recent nieuws

20 mei 2021
New Analysis Reinforces Cost-Effectiveness of the Oncotype DX Breast Recurrence Score® Test in Node-Positive Early-Stage Breast Cancer

24 maart 2021
New NCCN Breast Cancer Guidelines Recognise Oncotype DX Breast Recurrence Score® as the “Preferred” and Only Multigene Test to Predict Chemotherapy Benefit in Node-positive Early-stage Breast Cancer

9 december 2020
RxPONDER Study Results Demonstrate that the Oncotype DX® Test Can Now Spare Chemotherapy Use in the Majority of Women with Node-positive Early-stage Breast Cancer

2 oktober 2020
New Real-World Evidence Further Demonstrates the Clinical Utility of the Oncotype DX Breast Recurrence Score® Test, Beyond Clinical Risk Factors, in Guiding Chemotherapy Treatment Decisions in Patients with Early-stage Breast Cancer

29 mei 2020
New Data and Society Guidelines Support Value of Oncotype DX Breast Recurrence Score® Test in Guiding Neoadjuvant Treatment Decisions for Newly Diagnosed Patients

14 mei 2020
New Oncotype DX Real-world Evidence Shows for the First Time the Practice-changing Impact of TAILORx Results


2019

12 december 2019
New Evidence from Large Studies Highlights Value of Oncotype DX Breast Recurrence Score to Guide Chemotherapy Treatment in Young Patients with Node-negative or Node-positive Early-stage Breast Cancer

30 september 2019
New TAILORx Data, Published in JAMA Oncology, Add to Strong Evidence Base Reinforcing Unique Ability of Oncotype DX Breast Recurrence Score Test to Guide Chemotherapy Treatment

21 augustus 2019
New St. Gallen International Breast Cancer Guidelines Recommend Oncotype DX Breast Recurrence Score Test to Guide Chemotherapy for Node-Negative and Node-Positive Early-Stage Breast Cancer

21 juni 2019
German Federal Joint Committee (G-BA) Issues Exclusive Nationwide Reimbursement Decision for Oncotype DX Breast Recurrence Score Test

4 juni 2019
Secondary Analysis of Landmark TAILORx Results, Published in The New England Journal of Medicine, Affirms Unique Ability of Oncotype DX Breast Recurrence Score Test to Predict Chemotherapy Benefit, Guiding Adjuvant Therapy with Even Greater Precision

3 juni 2019
Updated ASCO Guidelines Establish TAILORx-defined Cutoffs for Determining Chemotherapy Benefit with the Oncotype DX Breast Recurrence Score Test in Node-negative Breast Cancer

25 maart 2019
New Long-Term Outcomes Data Reconfirm Value of Oncotype DX Breast Recurrence Score Test to Target Chemotherapy

2018 Archief
2017 Archief
Making cancer care smarter.™
X

Deze website maakt gebruik van cookies. Deze cookies verzamelen informatie over hoe bezoekers een website gebruiken, bijvoorbeeld welke pagina's het meest worden bezocht, en of ze foutmeldingen krijgen van webpagina's. Deze cookies verzamelen geen informatie die een bezoeker identificeert. De volledige informatie die door deze cookies wordt verzameld, wordt alleen gebruikt om de website te verbeteren. Met uw bezoek aan deze website gaat u ermee akkoord dat wij dit type cookies op uw apparaat kunnen plaatsen.